Lorne Steinberg Wealth Management Inc. Buys 2,160 Shares of Smith & Nephew plc (NYSE:SNN)

Lorne Steinberg Wealth Management Inc. grew its holdings in shares of Smith & Nephew plc (NYSE:SNN) by 0.9% in the fourth quarter, HoldingsChannel reports. The fund owned 233,155 shares of the medical equipment provider’s stock after purchasing an additional 2,160 shares during the quarter. Lorne Steinberg Wealth Management Inc.’s holdings in Smith & Nephew were worth $5,731,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of the business. Hara Capital LLC grew its position in shares of Smith & Nephew by 391.4% during the 4th quarter. Hara Capital LLC now owns 2,457 shares of the medical equipment provider’s stock valued at $60,000 after acquiring an additional 1,957 shares during the period. Sanctuary Advisors LLC grew its position in shares of Smith & Nephew by 7.8% during the 4th quarter. Sanctuary Advisors LLC now owns 24,904 shares of the medical equipment provider’s stock valued at $639,000 after acquiring an additional 1,810 shares during the period. Principal Securities Inc. grew its position in shares of Smith & Nephew by 87.6% during the 4th quarter. Principal Securities Inc. now owns 1,480 shares of the medical equipment provider’s stock valued at $36,000 after acquiring an additional 691 shares during the period. ABC Arbitrage SA bought a new stake in shares of Smith & Nephew during the 4th quarter valued at $4,847,000. Finally, Van ECK Associates Corp grew its position in shares of Smith & Nephew by 111.2% during the 4th quarter. Van ECK Associates Corp now owns 9,240 shares of the medical equipment provider’s stock valued at $227,000 after acquiring an additional 4,865 shares during the period. Institutional investors own 25.64% of the company’s stock.

Smith & Nephew Trading Up 1.0 %

SNN opened at $25.95 on Wednesday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.11 and a current ratio of 2.51. Smith & Nephew plc has a fifty-two week low of $23.65 and a fifty-two week high of $31.72. The firm’s fifty day moving average is $25.02 and its 200 day moving average is $27.37.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. StockNews.com downgraded shares of Smith & Nephew from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, November 12th. Berenberg Bank cut shares of Smith & Nephew from a “buy” rating to a “hold” rating in a research note on Wednesday, November 6th. Finally, Deutsche Bank Aktiengesellschaft cut shares of Smith & Nephew from a “buy” rating to a “hold” rating in a research note on Friday, November 1st.

Smith & Nephew Company Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.